ARTICLE | Emerging Company Profile
Duke spinout has new method to get T cell engagers across the blood-brain barrier
By Danielle Golovin, Senior Biopharma Analyst
December 18, 2024 12:40 AM UTC
Adaptin emerged from stealth in September with tech licensed from Duke University that can transport bispecific antibodies to tissues of interest, including the brain, and IND clearance from FDA to test its lead candidate in glioblastoma.
Naive T cells can’t cross the blood-brain barrier (BBB), but if the brain sends out signals that something is wrong, the T cells can express receptors on their cell surfaces that facilitate entry…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654368/adaptin-bispecifics-hitchhike-into-the-brain-using-edited-t-cells